Key Takeaway: C4 Therapeutics reported its second quarter 2026 financial results, highlighting the ongoing Phase 2 MOMENTUM trial and a Phase 1b trial of Cemsidomide in combination with Elranatamab. Both trials are on schedule to provide clinical data readouts in 2027. Additionally, promising Phase 1 data was presented at the European Hematology Association 2026 Congress, supporting Cemsidomide's potential as a leading treatment option.
Market Sentiment Analysis
POSITIVE FACTORS
Cemsidomide shows potential as a best-in-class treatment.
Ongoing trials are on track for data readouts in 2027.
Positive data presented at the EHA 2026 Congress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+115%
120-day peak, hindsight
Typical move
5.1%
average across 7 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
cemsidomide
Phase 2 · Multiple Myeloma
Full Press Release Details
Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology Association (EHA) 2026 Congress Further Support Cemsidomide’s Potential Best-in-Class Profile in
Frequently Asked Questions
What are the key highlights from C4 Therapeutics Q2 2026?
C4 Therapeutics reported ongoing trials for Cemsidomide and presented positive data at EHA 2026.
When will clinical data for Cemsidomide be available?
Clinical data readouts for Cemsidomide are expected in 2027.
What is the significance of the EHA 2026 Congress for C4 Therapeutics?
The EHA 2026 Congress showcased promising Phase 1 data for Cemsidomide.
What trials are currently ongoing for Cemsidomide?
Cemsidomide is involved in a Phase 2 MOMENTUM trial and a Phase 1b trial.